Pharma company Bristol-Myers Squibb has acquired protein engineering company Forbius. In Forbius' pipeline, there are numerous drug candidates for cancer and fibrosis, including drug AVID200 for treating tumors.
“With this acquisition, we extend our leading position in oncology by including new pathways that complement our expansive oncology pipeline with the potential to serve more patients with cancer, including those who may not respond to immunotherapy,” said Rupert Vessey, Executive Vice President & President, Research & Early Development, Bristol Myers Squibb.